NARI continues to gain from its expanded product portfolio. The company's expansion in China and Japan bodes well.

Inari Medical (NASDAQ:NARI – Free Report) had its price target increased by Piper Sandler from $52.00 to $80.00 in a report ...

Baird R W cut shares of Inari Medical (NASDAQ:NARI – Free Report) from a strong-buy rating to a hold rating in a research ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

Fintel reports that on January 7, 2025, Wells Fargo downgraded their outlook for Inari Medical (NasdaqGS:NARI) from ...

In a report released yesterday, William Plovanic from Canaccord Genuity downgraded Inari Medical (NARI – Research Report) to a Hold, with a ...

Inari Medical (NARI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mathew ...

Irvine-based Inari Medical Inc. has entered into an agreement to be acquired for $4.9 billion by medical technology company ...

After professing a hearty appetite for tuck-in M&A last year and signing a string of smaller deals, Stryker is now opening ...

Inari Medical’s top-line growth is primarily driven by its ClotTriever and FlowTriever products that target patients with venous thromboembolism (VTE) (with significant growth opportunities ...

On Tuesday, Baird analysts adjusted their stance on Inari Medical (TASE:PMCN) Inc. (NASDAQ:NARI), downgrading the stock from Outperform to Neutral and slightly reducing the price target to $80 ...